Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
We have previously demonstrated that the lack of TrkB signalling in cholecystokinin (CCK)-GABAergic neurons leads to glucocorticoid resistance
In summary, CPP-CAND is a FOXO4-p53 interaction inhibitor that is anticipated to offer cost-effectiveness, high selectivity, and safety compared to previously developed peptide interaction inhibitors
Medicine (Baltimore) 95: e2411, 2016
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Superior and Sustained Performance: Arthramid achieves 80-85% efficacy across multiple peer-reviewed studies Long-lasting Results: Clinical studies demonstrate sustained efficacy up to 2 years post-treatment Evidence-Based Efficacy: Double-blinded controlled studies confirm Arthramid outperforms triamcinolone steroid and hyaluronic acid Proven Safety Profile: Histopathology studies confirm successful joint integration and biocompatibility Robust Research Foundation: Results validated across six independent peer-reviewed studies spanning multiple research teams and geographical locations Unlike many joint treatments on the market, Arthramid is backed by a growing body of robust, real-world research, not just anecdotal outcomes
US$ 21.46
US$ 21.06
US$ 26.35